ADMA Adma Biologics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ADMA

Price (delayed)

$13.16

Market cap

$3.05B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.02

Enterprise value

$3.14B

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at ...

Highlights
The gross profit has soared by 132% YoY and by 25% from the previous quarter
The company's net income has surged by 92% YoY and by 87% QoQ
ADMA's quick ratio is down by 31% YoY but it is up by 13% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.admabiologics.com
Peers: NVAX RGEN CVM

Key stats

What are the main financial stats of ADMA
Market
Shares outstanding
231.81M
Market cap
$3.05B
Enterprise value
$3.14B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
19.54
Price to sales (P/S)
10.64
EV/EBIT
159.81
EV/EBITDA
111.87
EV/Sales
11.08
Earnings
Revenue
$283.18M
EBIT
$19.63M
EBITDA
$28.04M
Free cash flow
$16.13M
Per share
EPS
-$0.02
Free cash flow per share
$0.07
Book value per share
$0.67
Revenue per share
$1.24
TBVPS
$1.52
Balance sheet
Total assets
$350.88M
Total liabilities
$197.17M
Debt
$131.94M
Equity
$153.71M
Working capital
$223.33M
Liquidity
Debt to equity
0.86
Current ratio
5.21
Quick ratio
1.79
Net debt/EBITDA
3.09
Margins
EBITDA margin
9.9%
Gross margin
39.4%
Net margin
-1.3%
Operating margin
15.6%
Efficiency
Return on assets
-1.1%
Return on equity
-2.5%
Return on invested capital
5.3%
Return on capital employed
6.6%
Return on sales
6.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ADMA stock price

How has the Adma Biologics stock price performed over time
Intraday
0.61%
1 week
-1.5%
1 month
21.4%
1 year
238.3%
YTD
191.15%
QTD
17.71%

Financial performance

How have Adma Biologics's revenue and profit performed over time
Revenue
$283.18M
Gross profit
$111.54M
Operating income
$44.27M
Net income
-$3.64M
Gross margin
39.4%
Net margin
-1.3%
The gross profit has soared by 132% YoY and by 25% from the previous quarter
Adma Biologics's operating income has surged by 105% QoQ
The company's net margin has surged by 95% YoY and by 88% QoQ
The company's net income has surged by 92% YoY and by 87% QoQ

Growth

What is Adma Biologics's growth rate over time

Valuation

What is Adma Biologics stock price valuation
P/E
N/A
P/B
19.54
P/S
10.64
EV/EBIT
159.81
EV/EBITDA
111.87
EV/Sales
11.08
The EPS has surged by 92% year-on-year and by 85% since the previous quarter
The price to book (P/B) is 174% higher than the last 4 quarters average of 7.1
The equity has increased by 14% since the previous quarter and by 6% year-on-year
ADMA's price to sales (P/S) is 152% higher than its last 4 quarters average of 4.2 and 120% higher than its 5-year quarterly average of 4.8
ADMA's revenue has surged by 56% year-on-year and by 10% since the previous quarter

Efficiency

How efficient is Adma Biologics business performance
The company's return on invested capital has surged by 175% YoY
The return on sales has surged by 149% year-on-year
ADMA's ROE has soared by 93% YoY and by 87% QoQ
The company's return on assets has surged by 93% YoY and by 87% QoQ

Dividends

What is ADMA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ADMA.

Financial health

How did Adma Biologics financials performed over time
Adma Biologics's total assets is 78% more than its total liabilities
ADMA's quick ratio is down by 31% YoY but it is up by 13% QoQ
ADMA's current ratio is down by 28% YoY
The company's debt is 14% lower than its equity
Adma Biologics's debt to equity has decreased by 14% YoY and by 11% QoQ
The equity has increased by 14% since the previous quarter and by 6% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.